Patents by Inventor Julian S. Northen

Julian S. Northen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salt form
    Patent number: 11964972
    Abstract: Ditosylate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof; processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 23, 2024
    Assignee: CRT Pioneer Fund LP
    Inventors: Julian S. Northen, John Mykytiuk, Gillian Moore
  • Salt form
    Patent number: 11945814
    Abstract: Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof, processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 2, 2024
    Assignee: CRT Pioneer Fund LP
    Inventors: Julian S. Northen, John Mykytiuk, Gillian Moore
  • SALT FORM
    Publication number: 20210214351
    Abstract: Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof; processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 15, 2021
    Inventors: Julian S. Northen, John Mykytiuk, Gillian Moore
  • SALT FORM
    Publication number: 20210214350
    Abstract: Ditosylate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof; processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 15, 2021
    Inventors: Julian S. Northen, John Mykytiuk, Gillian Moore
  • Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound
    Patent number: 9062047
    Abstract: The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: June 23, 2015
    Assignee: Verona Pharma plc
    Inventors: Michael J. A. Walker, Bertrand M. C. Plouvier, Julian S. Northen, Philippe Fernandes
  • CRYSTALLINE FORM OF PYRIMIDIO[6,1-A] ISOQUINOLIN-4-ONE COMPOUND
    Publication number: 20130225616
    Abstract: The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.
    Type: Application
    Filed: August 9, 2011
    Publication date: August 29, 2013
    Applicant: VERONA PHARMA PLC
    Inventors: Michael J.A. Walker, Bertrand M.C. Plouvier, Julian S. Northen, Philippe Fernandes